The amended agreement strengthens Exor's long-term commitment to Philips while allowing the healthcare technology investor to increase its maximum shareholding from 20% to 22%.

The collaboration combines HanchorBio's immuno-oncology platform with Taiwan's national precision oncology programme to support biomarker-driven clinical development and translational research.

The collaboration pairs BeOne’s oncology pipeline with four clinical-stage RAS(ON) inhibitors while giving BeOne regional rights to the Revolution Medicines assets across selected Asian markets.

The collaboration will connect ChemoMetec’s XcytoMatic 30 cell counter with Roche’s Cedex Bio Analyzer and establish a joint go-to-market strategy for the combined bioprocess monitoring solution.

The long-term manufacturing agreement covers 55 oncology and non-oncology products across three Gland Pharma sites, with commercial revenue expected to begin in 2029.

The research collaboration combines Mediar’s fibrosis biology and antibody discovery capabilities with Ono’s drug development expertise to identify new treatments targeting fibro-inflammatory disease mechanisms.

The latest agreement strengthens the companies’ collaboration as they target a major central nervous system indication using AI-powered drug discovery.

The collaboration combines Biocytogen’s fully human antibody discovery platform with Whitehawk’s ADC expertise to develop novel cancer therapies with enhanced targeting potential.

The collaboration will evaluate Vivani’s implantable semaglutide technology as Novo Nordisk looks to expand treatment options beyond once-weekly injections.

The agreement with Sino Biopharmaceutical gives AstraZeneca ex-China rights to TQC3721, an experimental dual PDE3/4 inhibitor being developed for chronic respiratory diseases.

Genentech has secured global rights to a fragment-based drug discovery programme targeting a key regulator of breast cancer cell growth.

The agreement will deploy Insilico’s Pharma AI platform across Takeda’s pipeline to accelerate early-stage drug discovery and candidate selection.

Boltz has entered a strategic partnership with Takeda to deploy its biomolecular AI models across the Japanese pharmaceutical company’s discovery organisation, strengthening its position in the rapidly expanding field of AI-enabled drug design.

Merck & Co. has strengthened its commitment to AI-driven drug discovery through a new multi-year partnership with Protillion Biosciences, signing a deal worth up to $510 million focused on identifying and engineering novel therapeutic candidates.

Jazz Pharmaceuticals has expanded its oncology pipeline through a new collaboration with AbCellera, signing a deal worth more than $2.4 billion.

Alnylam Pharmaceuticals has entered a collaboration worth up to $2bn with Inceptive Nucleics, combining RNA interference (RNAi) drug development expertise with generative AI models specifically designed for sequence-based medicines.

Eli Lilly and Ascidian Therapeutics have entered into a multi-year strategic collaboration worth up to $1.9bn, focused on developing RNA exon-editing therapies for undisclosed monogenic kidney diseases.

The deal gives Regeneron access to Helicon peptide technology as pharma companies race to unlock previously “undruggable” intracellular targets.